Pharvaris (NASDAQ:PHVS) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Pharvaris (NASDAQ:PHVS) from a hold rating to a sell rating in a report published on Saturday morning.

A number of other research firms have also recently issued reports on PHVS. Morgan Stanley increased their price target on Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Oppenheimer boosted their target price on shares of Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.56.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $28.39 on Friday. Pharvaris has a 1 year low of $11.51 and a 1 year high of $29.80. The business’s 50-day moving average is $26.68 and its 200-day moving average is $24.73.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Pharvaris in the 2nd quarter valued at about $57,000. Geode Capital Management LLC boosted its position in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter. Legal & General Group Plc raised its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares during the last quarter. Finally, Amundi raised its position in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after buying an additional 27,416 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.